![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1767727
Ç÷°ü Æó¼â ±â±â ½ÃÀå : Á¦Ç° À¯Çüº°, ¾×¼¼½ºº°, ±¸¸Û »çÀÌÁ, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Vascular Closure Device Market, by Product Type, By Access, By Hole Size By End User and by Region |
Ç÷°ü Æó¼â ±â±â ½ÃÀåÀº 2025³â¿¡ 15¾ï 3,360¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 23¾ï 2,120¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â CAGRÀº 6.1%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
º¸°í¼ ¹üÀ§ | º¸°í¼ »ó¼¼ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 15¾ï 3,360¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â | 6.10% | 2032³â ±Ý¾× ¿¹Ãø | 23¾ï 2,120¸¸ ´Þ·¯ |
Ç÷°ü Æó¼â ±â±â´Â Ç÷°ü Á¶¿µ¼úÀ̳ª Ç÷°ü ¼ºÇü°ú °°Àº ½ÉÇ÷°ü ½Ã¼ú ÈÄ µ¿¸Æ õÀÚ¸¦ ºÀÇÕÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±â°èÀû ¶Ç´Â »ý¹°ÇÐÀû ¼ö´ÜÀ» ÅëÇØ ÀÚ¿¬ ÀÀ°í¸¦ ÃËÁøÇÏ¿© õÀÚ ºÎÀ§ÀÇ ÃâÇ÷À» ¸·´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Àü ¼¼°è Ç÷°ü Æó¼â ±â±âÀÇ »ç¿ë·®Àº Àü ¼¼°è ÁßÀçÀû ½ÉÀåÇÐ ¹× ¹æ»ç¼± Ä¡·áÀÇ ¼ºÀå°ú ÇÔ²² Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ÆíÀǼº Çâ»ó, ÀÔ¿ø ±â°£ ´ÜÃà, ¼öÀÛ¾÷ ¾Ð¹Ú¿¡ ºñÇØ ÇÕº´Áõ ¹ß»ý·ü °¨¼Ò·Î ÀÎÇØ Ç÷°ü Æó¼â ±â±â´Â Ç÷°ü Á¢±Ù ºÎÀ§ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.
¼¼°è Ç÷°ü Æó¼â ±â±â ½ÃÀåÀº Àα¸Åë°èÇÐÀû º¯ÈºÎÅÍ ±â¼ú ¹ßÀü±îÁö ´Ù¾çÇÑ ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÏ´Â °ÍÀº »ý¸®Àû ³ëÈ·Î ÀÎÇØ ½ÉÇ÷°üÁúȯ¿¡ °É¸®±â ½¬¿î ³ë³âÃþÀÇ Áõ°¡ÀÔ´Ï´Ù. ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÉÇ÷°ü°è ÁúȯÀÇ ¹ß»ý·üµµ Áõ°¡ÇÏ¿© Áø´Ü ¹× Ä¡·á ½Ã¼ú ÈÄ È¿°úÀûÀÎ Ç÷°ü Æó¼â ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ÀÇ·á ºÎ¹® Àüü¿¡¼ ÃÖ¼Òħ½À ¼ö¼ú(MIS)·ÎÀÇ ÀüȯÀÌ µÎµå·¯Áö°í ÀÖÀ¸¸ç, MIS ¼ö¼úÀº ±âÁ¸ÀÇ °³º¹ ¼ö¼ú¿¡ ºñÇØ °¨¿° À§ÇèÀ» ÁÙÀ̰í ÀÔ¿ø ±â°£À» ´ÜÃàÇϸç ȯÀÚÀÇ È¸º¹À» °¡¼ÓÈÇÕ´Ï´Ù. Ç÷°ü Æó¼â ±â±â´Â ºü¸¥ ÁöÇ÷, º¸Çà ½Ã°£ ´ÜÃà, ȯÀÚ ÆíÀǼº Çâ»ó µî ÀÌ·¯ÇÑ ¼ö¼ú¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
±â±¸ ±â¼úÀÇ ¹ßÀü ¶ÇÇÑ ¸Å¿ì Áß¿äÇϸç, ´õ ³ôÀº È¿°ú¿Í ½Ã¼ú ÈÄ ÇÕº´Áõ À§ÇèÀ» °¨¼Ò½ÃŰ´Â ±â±¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. µðÀÚÀÎ ¹× Àç·áÀÇ °³¼±À¸·Î ¹ÐÆó¼ºÀÌ Çâ»óµÇ°í, ´Ù¾çÇÑ ÇØºÎÇÐÀû ÇüÅÂ¿Í ÃµÀÚ Å©±â¿¡ ¸Â´Â Á¦Ç°ÀÌ Åº»ýÇß½À´Ï´Ù. ¹Ý¸é, ÀÌ·¯ÇÑ Ã·´Ü ±â±â¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀº º¸±Þ¿¡ °É¸²µ¹ÀÌ µÇ±âµµ ÇÕ´Ï´Ù. ƯÁ¤ ÀÇ·á ½Ã½ºÅÛ¿¡¼ÀÇ ºÎÁ·ÇÑ »óȯÀº ÀÌ ¹®Á¦¸¦ ´õ¿í ¾ÇȽÃÄÑ È¯ÀÚ°¡ ÀÌ·¯ÇÑ ±â¼úÀ» »ç¿ëÇÏ´Â °ÍÀ» ¾î·Æ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ÁöÇ÷À» À§ÇÑ ±âÁ¸ÀÇ ´ë¾ÈÀÌ Á¸ÀçÇÏÁö¸¸, ¼öµ¿ ¾Ð¹Ú°ú °°ÀÌ È¸º¹¿¡ ½Ã°£ÀÌ ¿À·¡ °É¸®°Å³ª ÇÕº´Áõ À§ÇèÀÌ ³ô¾ÆÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
ÀÌ ½ÃÀåÀº ƯÈ÷ ÇöÀç ÇコÄɾ ´ëÇÑ ÅõÀÚ¿Í ÇコÄɾî ÀÎÇÁ¶ó°¡ °ÈµÇ°í ÀÖ´Â ½ÅÈï±¹¿¡¼ Å« ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº º¹ÀâÇÑ ½Ã¼ú¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â »ýºÐÇØ¼º Àç·á·Î ¸¸µé¾îÁø Á¦Ç° µî ÇöÀç ÁøÇà ÁßÀÎ »õ·Î¿î ÀåÄ¡ °³¹ßÀº Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ºñ¿ë ¹× »óȯ ¹®Á¦¿Í °°Àº °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖÁö¸¸, ±â¼ú ¹ßÀü°ú MIS¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî Ç÷°ü Æó¼â ±â±âÀÇ ÀåÁ¡Àº ¾ÕÀ¸·Îµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¿¹¸¦ µé¾î, 2021³â 1¿ù, ´õ ³ªÀº ȯÀÚ °á°ú¸¦ ÃËÁøÇÏ´Â Çõ½ÅÀûÀÎ ÀÇ·á ¼Ö·ç¼Ç Á¦°ø¿¡ ÁÖ·ÂÇÏ´Â ÀÇ·á ±â¼ú ȸ»çÀÎ Haemonetics CorporationÀº Ç÷°ü Æó¼â ½Ã½ºÅÛ Á¦Á¶¾÷üÀÎ ºñ»óÀå ±â¾÷ Cardiva Medical, Inc. Àμö °è¾àÀ» ü°áÇÏ¿´½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
Vascular Closure Device Market is estimated to be valued at USD 1,533.6 Mn in 2025 and is expected to reach USD 2,321.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 1,533.6 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 6.10% | 2032 Value Projection: | USD 2,321.2 Mn |
Vascular closure devices help seal arterial punctures after a cardiovascular procedure such as angiography or angioplasty. They help stop bleeding at the puncture site by accelerating natural clotting through mechanical or biological means. The global usage of vascular closure devices has been increasing with growth in interventional cardiology and radiology procedures worldwide. Improved patient comfort, reduced hospital stay times, and lower complication rates compared to manual compression methods have made vascular closure devices an integral part of vascular access site management.
The global vascular closure device market is growing substantially, propelled by a confluence of factors ranging from demographic shifts to technological progress. A significant contributor to this growth is the rising geriatric population which is more susceptible to cardiovascular diseases due to physiological aging. As the elderly population grows, so does the incidence of cardiovascular conditions, thereby increasing the demand for effective vascular closure devices following diagnostic and therapeutic procedures. Simultaneously, a notable shift towards minimally invasive surgeries (MIS) across the healthcare sector. MIS procedures reduce the risk of infection, shorten hospital stays, and speed up patient recovery times compared to traditional open surgeries. Vascular closure devices play a key role in these procedures by providing rapid hemostasis, reducing time to ambulation, and enhancing patient comfort.
Advancements in device technology have also been pivotal, leading to devices that offer greater efficacy and a reduced risk of post-procedure complications. Enhanced designs and materials have yielded products with improved sealing capabilities and compatibility with various anatomies and puncture sizes. On the other side of the spectrum, the high costs associated with these advanced devices can act as a barrier to their widespread adoption. The lack of reimbursement in certain healthcare systems further exacerbates this issue, making it challenging for patients to access these technologies. While existing alternatives for achieving hemostasis, such as manual compression, exist, they often come with longer recovery times and elevated risks of complications, thereby providing an opening for the adoption of advanced vascular closure devices.
The market is ripe with opportunities, especially within emerging economies that are currently witnessing increased healthcare investments and enhancements to their healthcare infrastructure. The significant potential in the ongoing development of novel devices, including those made from biodegradable materials, commonly used in complex procedures like transcatheter aortic valve replacement (TAVR).Overall, while challenges like cost and reimbursement issues persist, the benefits of vascular closure devices, including the advancements in technology and rising demands for MIS, are likely to continue to drive market growth.
For instance, in January 2021, Haemonetics Corporation, a medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, entered into a definitive agreement to acquire privately-held Cardiva Medical, Inc., a manufacturer of vascular closure systems.
Key features of the study